Matinas Biopharma Hl (MTNB) 0.5200 $MTNB
Matinas BioPharma to Present at the 17th Annual BIO CEO & Investor Conference on February 9, 2015
GlobeNewswire - Thu Feb 05, 7:07AM CST
Matinas BioPharma Holdings, Inc. ("Matinas BioPharma" or the "Company"
(OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of lipid-based prescription therapeutics for the treatment of metabolic and cardiovascular conditions and the treatment of infectious diseases, announced today that it will be presenting at the 17th Annual BIO CEO & Investor Conference being held February 9-10, 2015, at the Waldorf Astoria in New York, New York.
Matinas Biopharma Acquires Aquarius Biotechnologies
Jason Napodano, CFA - at Seeking Alpha - Wed Feb 04, 6:09PM CST
Matinas BioPharma Establishes Lipid-Based, Anti-Infective Platform, With Acquisition of Aquarius BioTechnologies Inc.
GlobeNewswire - Fri Jan 30, 7:25AM CST
- Novel lipid-crystal nano-particle cochleate formulation delivery platform with opportunity for broad use in anti-infectives featuring targeted delivery and multi-organ protection -
Matinas BioPharma Holdings, Inc. - Increasing Evidence That Elevated Triglycerides Cause Cardiovascular Events
ACCESSWIRE - Thu Jan 08, 12:18PM CST
New York, NY / ACCESSWIRE / January 8, 2015 / Matinas BioPharma Holdings, Inc. (OTCQB: MTNB) today published a new blog post on The Chairman's Blog, written by the Company's Co-Founder and CEO, Roelof Rongen. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
Matinas BioPharma to Present at the Biotech Showcase 2015 Conference on January 14, 2015
GlobeNewswire - Wed Jan 07, 6:35AM CST
Matinas BioPharma Holdings, Inc. ("Matinas BioPharma" or the "Company" (OTCQB:MTNB), an emerging biopharmaceutical company focused on the development and commercialization of omega-3 fatty acid-based prescription therapeutics for the treatment of cardiovascular and metabolic conditions, announced today that Roelof Rongen, President and Chief Executive Officer, will be presenting at Biotech Showcase 2015 on Wednesday, January 14, 2015.
Matinas BioPharma Provides Update on Clinical Development Program for MAT9001 Following FDA Feedback on IND Submission
GlobeNewswire - Tue Dec 23, 7:05AM CST
Matinas BioPharma Holdings, Inc. ("Matinas BioPharma" or the "Company" (OTCQB:MTNB), an emerging biopharmaceutical company focused on the development and commercialization of omega-3 fatty acid-based prescription therapeutics for the treatment of cardiovascular and metabolic conditions, announced today that the Company has received advice and recommendations from the United States Food and Drug Administration (FDA) on its Investigational New Drug Application (IND) for its product candidate, MAT9001.
Eight Companies Webcast Live to Investors, December 4th at VirtualInvestorConferences.com
PR Newswire - Tue Dec 02, 7:29AM CST
CEOs and top executives to take questions in real-time during formal roadshow presentations as well as meet and "chat" in virtual trade booths
SMLR: 4.54 (+0.20), ONVO: 6.34 (+0.07), CYTX: 0.47 (unch), IAG: 2.23 (-0.08)
Matinas BioPharma Appoints Leading Clinical Lipid Specialist and Metabolism Researcher, Kevin C. Maki, Ph.D., to Scientific Advisory Board
GlobeNewswire - Mon Nov 24, 6:05AM CST
Matinas BioPharma Holdings, Inc. ("Matinas BioPharma" or the "Company" (OTCQB:MTNB), an emerging biopharmaceutical company focused on the development and commercialization of omega-3 fatty acid-based prescription therapeutics for the treatment of cardiovascular and metabolic conditions, announced today that it has appointed Kevin C. Maki, Ph.D. to its recently formed Scientific Advisory Board (SAB).
Matinas BioPharma to Present at Two Investor Conferences in Early December
GlobeNewswire - Thu Nov 20, 9:12AM CST
- LD Micro Main Event VII Presentation and Live Audio Webcast on Wednesday, December 3, 2014, at 3:00 p.m. PST / 6:00 p.m. EST -
Matinas BioPharma Commences Dosing in First Human Trial of Lead Product Candidate MAT9001
GlobeNewswire - Wed Nov 12, 6:35AM CST
Matinas BioPharma Holdings, Inc. ("Matinas BioPharma" or the "Company" (OTCQB:MTNB), an emerging biopharmaceutical company focused on the development and commercialization of omega-3 fatty acid-based prescription therapeutics for the treatment of cardiovascular and metabolic conditions, today announced it has commenced dosing in the first-in-human study of MAT9001. The Company's initial trial is being conducted in Canada and is a pharmacokinetic and pharmacodynamic (PK/PD) study of MAT9001 versus an active comparator.
Matinas Biopharma Receives Notice of Allowance of U.S. Patent for MAT9001
GlobeNewswire - Mon Nov 10, 6:35AM CST
Matinas BioPharma Holdings, Inc. ("Matinas BioPharma" or the "Company" (OTCQB:MTNB), an emerging biopharmaceutical company focused on the development and commercialization of omega-3 fatty acid-based prescription therapeutics for the treatment of cardiovascular and metabolic conditions, today announced it received a Notice of Allowance from the U.S. Patent and Trademark Office ("USPTO" for U.S. Patent Application Serial No. 14/101,165 entitled, "Methods of Administering Compositions Comprising Docosapentaenoic Acid." Upon issuance, the patent will provide intellectual property protection through 2033.
Matinas BioPharma Appoints Cardiologist and Lipidology Expert Christie M. Ballantyne, M.D. to Scientific Advisory Board
GlobeNewswire - Tue Nov 04, 6:39AM CST
Matinas BioPharma Holdings, Inc. ("Matinas BioPharma" or the "Company" (OTCQB:MTNB), an emerging biopharmaceutical company focused on the development and commercialization of omega-3 fatty acid-based prescription therapeutics for the treatment of cardiovascular and metabolic conditions, today announced that it has established a new Scientific Advisory Board (SAB) and appointed internationally renowned cardiologist Christie M. Ballantyne, M.D., as its first SAB member. The Company expects to add additional SAB members over the coming months.
Matinas BioPharma Receives Authorization From Health Canada to Initiate Human Clinical Study of Lead Product Candidate MAT9001
GlobeNewswire - Wed Oct 29, 6:35AM CDT
Matinas BioPharma Holdings, Inc. ("Matinas BioPharma" or the "Company" (OTCQB:MTNB), an emerging biopharmaceutical company focused on the development and commercialization of omega-3 fatty acid-based prescription therapeutics for the treatment of cardiovascular and metabolic conditions, today announced that it has received a Notice of Authorization from Health Canada to initiate the first-in-human study of MAT9001. The Company expects to commence dosing in this pharmacokinetic and pharmacodynamic (PK/PD) study of MAT9001 in Canada during the fourth quarter of 2014 and report topline data in the second quarter of 2015.
Matinas BioPharma Submits Investigational New Drug Application for Lead Product Candidate MAT9001 for the Treatment of Severe Hypertriglyceridemia
GlobeNewswire - Mon Oct 20, 8:38AM CDT
Matinas BioPharma Holdings, Inc. ("Matinas BioPharma" or the "Company" (OTCQB:MTNB), an emerging biopharmaceutical company focused on the development and commercialization of omega-3 fatty acid-based prescription therapeutics for the treatment of cardiovascular and metabolic conditions, announced today that the Company has submitted an Investigational New Drug application (IND) for MAT9001 to the United States Food and Drug Administration (FDA).
Matinas BioPharma to Present at the 13th Annual BIO Investor Forum on Wednesday, October 8, 2014
GlobeNewswire - Tue Sep 30, 6:35AM CDT
Matinas BioPharma Holdings, Inc. ("Matinas BioPharma" or the "Company" (OTCQB:MTNB), an emerging biopharmaceutical company focused on the development and commercialization of omega-3 fatty acid-based prescription therapeutics for the treatment of cardiovascular and metabolic conditions, today announced that Roelof Rongen, President and Chief Executive Officer, will be presenting at the 13th Annual BIO Investor Forum being held October 7-8, 2014 at the Palace Hotel in San Francisco, California. The annual BIO Investor Forum is hosted by the Biotechnology Industry Organization (BIO) and features leading private and emerging public companies.
Matinas BioPharma - "Clinical Treatment Guidelines for Dyslipidemia Continue to Evolve"
ACCESSWIRE - Mon Sep 29, 9:30AM CDT
New York, NY / September 29, 2014 / Matinas BioPharma Holdings, Inc. (OTCQB: MTNB) today published a new blog post on The Chairman's Blog, written by the Company's President and Chief Executive Officer, Roelof Rongen. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
SeeThruEquity Announces Fall Microcap Investor Conference To Be Held September 11, 2014
ACCESSWIRE - Mon Sep 08, 4:27PM CDT
Conference Being Held at Convene Times Square in Midtown
SeeThruEquity Fall Microcap Investor Conference To Be Held September 11, 2014
ACCESSWIRE - Mon Sep 08, 8:13AM CDT
Conference Being Held at Convene Times Square in Midtown
Matinas BioPharma Holdings, Inc. Approved to Trade on OTCQB Venture Stage Marketplace
GlobeNewswire - Mon Sep 08, 6:36AM CDT
Matinas BioPharma Holdings, Inc. ("Matinas BioPharma" or the "Company" (OTCQB:MTNB), an emerging biopharmaceutical company focused on the development and commercialization of omega-3 fatty acid-based prescription therapeutics for the treatment of cardiovascular and metabolic conditions, today announced it has been approved to continue quotation of its securities on OTCQB, the venture stage marketplace (the "OTCQB" , effective as of September 5, 2014. The Company's shares will continue to trade under the ticker symbol "MTNB."
Matinas BioPharma to Present at Three Investor Conferences in September
GlobeNewswire - Thu Sep 04, 6:05AM CDT
- Rodman & Renshaw 16 Annual Global Investment Presentation and Live Audio Webcast on September 9, 2014 -
Matinas BioPharma to Present at the 17th Annual BIO CEO & Investor Conference on February 9, 2015
GlobeNewswire - Thu Feb 05, 7:07AM CST
Matinas BioPharma Holdings, Inc. ("Matinas BioPharma" or the "Company"
(OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of lipid-based prescription therapeutics for the treatment of metabolic and cardiovascular conditions and the treatment of infectious diseases, announced today that it will be presenting at the 17th Annual BIO CEO & Investor Conference being held February 9-10, 2015, at the Waldorf Astoria in New York, New York. Matinas Biopharma Acquires Aquarius Biotechnologies
Jason Napodano, CFA - at Seeking Alpha - Wed Feb 04, 6:09PM CST
Matinas BioPharma Establishes Lipid-Based, Anti-Infective Platform, With Acquisition of Aquarius BioTechnologies Inc.
GlobeNewswire - Fri Jan 30, 7:25AM CST
- Novel lipid-crystal nano-particle cochleate formulation delivery platform with opportunity for broad use in anti-infectives featuring targeted delivery and multi-organ protection -
Matinas BioPharma Holdings, Inc. - Increasing Evidence That Elevated Triglycerides Cause Cardiovascular Events
ACCESSWIRE - Thu Jan 08, 12:18PM CST
New York, NY / ACCESSWIRE / January 8, 2015 / Matinas BioPharma Holdings, Inc. (OTCQB: MTNB) today published a new blog post on The Chairman's Blog, written by the Company's Co-Founder and CEO, Roelof Rongen. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
Matinas BioPharma to Present at the Biotech Showcase 2015 Conference on January 14, 2015
GlobeNewswire - Wed Jan 07, 6:35AM CST
Matinas BioPharma Holdings, Inc. ("Matinas BioPharma" or the "Company"
(OTCQB:MTNB), an emerging biopharmaceutical company focused on the development and commercialization of omega-3 fatty acid-based prescription therapeutics for the treatment of cardiovascular and metabolic conditions, announced today that Roelof Rongen, President and Chief Executive Officer, will be presenting at Biotech Showcase 2015 on Wednesday, January 14, 2015. Matinas BioPharma Provides Update on Clinical Development Program for MAT9001 Following FDA Feedback on IND Submission
GlobeNewswire - Tue Dec 23, 7:05AM CST
Matinas BioPharma Holdings, Inc. ("Matinas BioPharma" or the "Company"
(OTCQB:MTNB), an emerging biopharmaceutical company focused on the development and commercialization of omega-3 fatty acid-based prescription therapeutics for the treatment of cardiovascular and metabolic conditions, announced today that the Company has received advice and recommendations from the United States Food and Drug Administration (FDA) on its Investigational New Drug Application (IND) for its product candidate, MAT9001. Eight Companies Webcast Live to Investors, December 4th at VirtualInvestorConferences.com
PR Newswire - Tue Dec 02, 7:29AM CST
CEOs and top executives to take questions in real-time during formal roadshow presentations as well as meet and "chat" in virtual trade booths
SMLR: 4.54 (+0.20), ONVO: 6.34 (+0.07), CYTX: 0.47 (unch), IAG: 2.23 (-0.08)
Matinas BioPharma Appoints Leading Clinical Lipid Specialist and Metabolism Researcher, Kevin C. Maki, Ph.D., to Scientific Advisory Board
GlobeNewswire - Mon Nov 24, 6:05AM CST
Matinas BioPharma Holdings, Inc. ("Matinas BioPharma" or the "Company"
(OTCQB:MTNB), an emerging biopharmaceutical company focused on the development and commercialization of omega-3 fatty acid-based prescription therapeutics for the treatment of cardiovascular and metabolic conditions, announced today that it has appointed Kevin C. Maki, Ph.D. to its recently formed Scientific Advisory Board (SAB). Matinas BioPharma to Present at Two Investor Conferences in Early December
GlobeNewswire - Thu Nov 20, 9:12AM CST
- LD Micro Main Event VII Presentation and Live Audio Webcast on Wednesday, December 3, 2014, at 3:00 p.m. PST / 6:00 p.m. EST -
Matinas BioPharma Commences Dosing in First Human Trial of Lead Product Candidate MAT9001
GlobeNewswire - Wed Nov 12, 6:35AM CST
Matinas BioPharma Holdings, Inc. ("Matinas BioPharma" or the "Company"
(OTCQB:MTNB), an emerging biopharmaceutical company focused on the development and commercialization of omega-3 fatty acid-based prescription therapeutics for the treatment of cardiovascular and metabolic conditions, today announced it has commenced dosing in the first-in-human study of MAT9001. The Company's initial trial is being conducted in Canada and is a pharmacokinetic and pharmacodynamic (PK/PD) study of MAT9001 versus an active comparator. Matinas Biopharma Receives Notice of Allowance of U.S. Patent for MAT9001
GlobeNewswire - Mon Nov 10, 6:35AM CST
Matinas BioPharma Holdings, Inc. ("Matinas BioPharma" or the "Company"
(OTCQB:MTNB), an emerging biopharmaceutical company focused on the development and commercialization of omega-3 fatty acid-based prescription therapeutics for the treatment of cardiovascular and metabolic conditions, today announced it received a Notice of Allowance from the U.S. Patent and Trademark Office ("USPTO" for U.S. Patent Application Serial No. 14/101,165 entitled, "Methods of Administering Compositions Comprising Docosapentaenoic Acid." Upon issuance, the patent will provide intellectual property protection through 2033. Matinas BioPharma Appoints Cardiologist and Lipidology Expert Christie M. Ballantyne, M.D. to Scientific Advisory Board
GlobeNewswire - Tue Nov 04, 6:39AM CST
Matinas BioPharma Holdings, Inc. ("Matinas BioPharma" or the "Company"
(OTCQB:MTNB), an emerging biopharmaceutical company focused on the development and commercialization of omega-3 fatty acid-based prescription therapeutics for the treatment of cardiovascular and metabolic conditions, today announced that it has established a new Scientific Advisory Board (SAB) and appointed internationally renowned cardiologist Christie M. Ballantyne, M.D., as its first SAB member. The Company expects to add additional SAB members over the coming months. Matinas BioPharma Receives Authorization From Health Canada to Initiate Human Clinical Study of Lead Product Candidate MAT9001
GlobeNewswire - Wed Oct 29, 6:35AM CDT
Matinas BioPharma Holdings, Inc. ("Matinas BioPharma" or the "Company"
(OTCQB:MTNB), an emerging biopharmaceutical company focused on the development and commercialization of omega-3 fatty acid-based prescription therapeutics for the treatment of cardiovascular and metabolic conditions, today announced that it has received a Notice of Authorization from Health Canada to initiate the first-in-human study of MAT9001. The Company expects to commence dosing in this pharmacokinetic and pharmacodynamic (PK/PD) study of MAT9001 in Canada during the fourth quarter of 2014 and report topline data in the second quarter of 2015. Matinas BioPharma Submits Investigational New Drug Application for Lead Product Candidate MAT9001 for the Treatment of Severe Hypertriglyceridemia
GlobeNewswire - Mon Oct 20, 8:38AM CDT
Matinas BioPharma Holdings, Inc. ("Matinas BioPharma" or the "Company"
(OTCQB:MTNB), an emerging biopharmaceutical company focused on the development and commercialization of omega-3 fatty acid-based prescription therapeutics for the treatment of cardiovascular and metabolic conditions, announced today that the Company has submitted an Investigational New Drug application (IND) for MAT9001 to the United States Food and Drug Administration (FDA). Matinas BioPharma to Present at the 13th Annual BIO Investor Forum on Wednesday, October 8, 2014
GlobeNewswire - Tue Sep 30, 6:35AM CDT
Matinas BioPharma Holdings, Inc. ("Matinas BioPharma" or the "Company"
(OTCQB:MTNB), an emerging biopharmaceutical company focused on the development and commercialization of omega-3 fatty acid-based prescription therapeutics for the treatment of cardiovascular and metabolic conditions, today announced that Roelof Rongen, President and Chief Executive Officer, will be presenting at the 13th Annual BIO Investor Forum being held October 7-8, 2014 at the Palace Hotel in San Francisco, California. The annual BIO Investor Forum is hosted by the Biotechnology Industry Organization (BIO) and features leading private and emerging public companies. Matinas BioPharma - "Clinical Treatment Guidelines for Dyslipidemia Continue to Evolve"
ACCESSWIRE - Mon Sep 29, 9:30AM CDT
New York, NY / September 29, 2014 / Matinas BioPharma Holdings, Inc. (OTCQB: MTNB) today published a new blog post on The Chairman's Blog, written by the Company's President and Chief Executive Officer, Roelof Rongen. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
SeeThruEquity Announces Fall Microcap Investor Conference To Be Held September 11, 2014
ACCESSWIRE - Mon Sep 08, 4:27PM CDT
Conference Being Held at Convene Times Square in Midtown
SeeThruEquity Fall Microcap Investor Conference To Be Held September 11, 2014
ACCESSWIRE - Mon Sep 08, 8:13AM CDT
Conference Being Held at Convene Times Square in Midtown
Matinas BioPharma Holdings, Inc. Approved to Trade on OTCQB Venture Stage Marketplace
GlobeNewswire - Mon Sep 08, 6:36AM CDT
Matinas BioPharma Holdings, Inc. ("Matinas BioPharma" or the "Company"
(OTCQB:MTNB), an emerging biopharmaceutical company focused on the development and commercialization of omega-3 fatty acid-based prescription therapeutics for the treatment of cardiovascular and metabolic conditions, today announced it has been approved to continue quotation of its securities on OTCQB, the venture stage marketplace (the "OTCQB" , effective as of September 5, 2014. The Company's shares will continue to trade under the ticker symbol "MTNB." Matinas BioPharma to Present at Three Investor Conferences in September
GlobeNewswire - Thu Sep 04, 6:05AM CDT
- Rodman & Renshaw 16 Annual Global Investment Presentation and Live Audio Webcast on September 9, 2014 -
